Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM Archives of Physiology and Biochemistry Pub Date : 2024-12-01 Epub Date: 2023-11-03 DOI:10.1080/13813455.2023.2258559

Mostafa Araj-Khodaei, Mohammad Hossein Ayati, Akbar Azizi Zeinalhajlou, Tannaz Novinbahador, Mehdi Yousefi, Mahdi Shiri, Ata Mahmoodpoor, Ali Shamekh, Nazli Namazi, Sarvin Sanaie

{"title":"Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review.","authors":"Mostafa Araj-Khodaei, Mohammad Hossein Ayati, Akbar Azizi Zeinalhajlou, Tannaz Novinbahador, Mehdi Yousefi, Mahdi Shiri, Ata Mahmoodpoor, Ali Shamekh, Nazli Namazi, Sarvin Sanaie","doi":"10.1080/13813455.2023.2258559","DOIUrl":null,"url":null,"abstract":"Introduction: A growing number of studies have thus far showed the association between type 2 diabetes mellitus (DM) and the intestinal microbiome homoeostasis. As reported, the gut microflora can be significantly different in patients with type 2 DM (T2DM) compared to those in healthy individuals.Methods: The authors collected the relevant articles published until 2022 and these are carefully selected from three scientific databases based on keywords.Discussion: This review highlights research on the anti-diabetic properties of berberine (BBR)-induced glucagon-like peptide-1 (GLP-1), as a glucose-lowering factor and a balance regulator in the microbial flora of the intestines, which plays an important role in adjusting the signalling pathways affecting insulin secretion.Results: Considering the anti-diabetic characteristics of the BBR-induced GLP-1, BBR makes a promising complementary treatment for reducing the clinical symptoms of DM by reducing the hyperglycaemia. Berberin might be a safe and effective drug for T2DM with little or no adverse effects.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"678-685"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2023.2258559","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A growing number of studies have thus far showed the association between type 2 diabetes mellitus (DM) and the intestinal microbiome homoeostasis. As reported, the gut microflora can be significantly different in patients with type 2 DM (T2DM) compared to those in healthy individuals.

Methods: The authors collected the relevant articles published until 2022 and these are carefully selected from three scientific databases based on keywords.

Discussion: This review highlights research on the anti-diabetic properties of berberine (BBR)-induced glucagon-like peptide-1 (GLP-1), as a glucose-lowering factor and a balance regulator in the microbial flora of the intestines, which plays an important role in adjusting the signalling pathways affecting insulin secretion.

Results: Considering the anti-diabetic characteristics of the BBR-induced GLP-1, BBR makes a promising complementary treatment for reducing the clinical symptoms of DM by reducing the hyperglycaemia. Berberin might be a safe and effective drug for T2DM with little or no adverse effects.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

黄连素诱导的胰高血糖素样肽-1及其控制2型糖尿病的机制：综合途径综述。

引言：到目前为止，越来越多的研究表明2型糖尿病（DM）与肠道微生物组稳态之间存在关联。据报道，2型患者的肠道菌群可能存在显著差异 DM（T2DM）与健康个体相比。方法：作者收集了截至2022年发表的相关文章，并根据关键词从三个科学数据库中仔细挑选。讨论：这篇综述重点研究了黄连素（BBR）诱导的胰高血糖素样肽-1（GLP-1）的抗糖尿病特性，GLP-1是一种降血糖因子和肠道微生物群中的平衡调节因子，在调节影响胰岛素分泌的信号通路中起着重要作用。结果：考虑到BBR诱导的GLP-1的抗糖尿病特性，BBR通过降低高血糖来减少糖尿病的临床症状，是一种很有前途的补充治疗方法。柏培林可能是一种安全有效的治疗T2DM的药物，不良反应很少或没有。提示：黄连素在肠道中通过PLC2途径诱导GLP-1胰岛素分泌黄连素诱导的GLP-1降低线粒体应激并将细胞色素c从线粒体中重新定位。黄连素通过改变细菌特性诱导肠内GLP-1分泌，从而可能减轻糖尿病症状。黄连素诱导的SCFA产生，SCFA导致肠L细胞分泌GLP-1。因此，防止线粒体损伤、减少脂肪组织脂肪和减少氧化应激是BBR诱导的GLP-1的结果之一，其有限的副作用和较高的可用性使其成为治疗糖尿病的一种有前途的辅助药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.